MediTox is delighted to participate in NLSDays 2026, the premier Nordic meeting place for the life science and health technology community. Join us at our booth to learn more about the latest news, explore potential collaborations, and discuss how we can work together to advance healthcare innovation. If you would like to arrange a dedicated meeting with our team, you can book a meeting in advance via the NLSDays Partnering System or contact us directly at business@meditox.eu. We look forward to welcoming you in Stockholm and exploring new partnership opportunities.

The Czech Republic Pavilion was officially opened yesterday at the BIO International Convention in San Diego. We're proud that MediTox is once again part of this outstanding event and look forward to meeting partners, colleagues, and new contacts throughout the week.

At first glance, both aim to understand safety. But their roles in drug development are fundamentally different. Non-GLP tox is about learning • Early-stage, flexible, hypothesis-driven • Helps define dose range, target organs, and study design • Fast and cost-effective, but not suitable for regulatory submission GLP tox is about proving • Conducted under strict regulatory standards (documentation, QA, traceability) • Generates data for IND/CTA submissions • Less flexible, more expensive—but fully auditable and accepted by regulators Briefly said, Non-GLP studies guide decisions, GLP studies justify them. Getting the transition right between the two is often what determines whether a program moves forward smoothly—or stalls.